Title:
SIGLEC-9 ECD FUSION MOLECULES AND METHODS OF USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2021/091885
Kind Code:
A3
Abstract:
The present disclosure is generally directed to Siglec-9 ECDs and Siglec-9 ECD fusion molecules, and methods of treatment using Siglec-9 ECDs and Siglec-9 ECD fusion molecules.
Inventors:
LIANG SPENCER (US)
NALLE SAMUEL (US)
SUN JEONGHOON (US)
LONG HUA (US)
BANKOTI RASHMI (US)
NALLE SAMUEL (US)
SUN JEONGHOON (US)
LONG HUA (US)
BANKOTI RASHMI (US)
Application Number:
PCT/US2020/058687
Publication Date:
June 17, 2021
Filing Date:
November 03, 2020
Export Citation:
Assignee:
ALECTOR LLC (US)
International Classes:
C07K14/47
Domestic Patent References:
| WO2017075432A2 | 2017-05-04 | |||
| WO2017085166A1 | 2017-05-26 |
Other References:
FOUSSIAS G ET AL: "Identification and Molecular Characterization of a Novel Member of the Siglec Family (SIGLEC9)", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 67, no. 2, 15 July 2000 (2000-07-15), pages 171 - 178, XP004437889, ISSN: 0888-7543, DOI: 10.1006/GENO.2000.6208
NGUYEN D H ET AL: "Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs", EXPERIMENTAL HEMATALOGY, ELSEVIER INC, US, vol. 34, no. 6, 1 June 2006 (2006-06-01), pages 728 - 735, XP027879571, ISSN: 0301-472X, [retrieved on 20060601]
NOVOPROLABS: "Commonly used leader peptide sequences for mammalian cells expression", 21 April 2018 (2018-04-21), XP002802721, Retrieved from the Internet [retrieved on 20120419]
STEPHAN VON GUNTEN ET AL: "Basic and Clinical Immunology of Siglecs", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 1143, no. 1, 1 November 2008 (2008-11-01), US, pages 61 - 82, XP055372327, ISSN: 0077-8923, DOI: 10.1196/annals.1443.011
DALY JOHN ET AL: "Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer", FRONTIERS IN IMMUNOLOGY, vol. 10, 1 January 2019 (2019-01-01), pages 1047, XP055797688, DOI: 10.3389/fimmu.2019.01047
NGUYEN D H ET AL: "Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs", EXPERIMENTAL HEMATALOGY, ELSEVIER INC, US, vol. 34, no. 6, 1 June 2006 (2006-06-01), pages 728 - 735, XP027879571, ISSN: 0301-472X, [retrieved on 20060601]
NOVOPROLABS: "Commonly used leader peptide sequences for mammalian cells expression", 21 April 2018 (2018-04-21), XP002802721, Retrieved from the Internet
STEPHAN VON GUNTEN ET AL: "Basic and Clinical Immunology of Siglecs", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 1143, no. 1, 1 November 2008 (2008-11-01), US, pages 61 - 82, XP055372327, ISSN: 0077-8923, DOI: 10.1196/annals.1443.011
DALY JOHN ET AL: "Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer", FRONTIERS IN IMMUNOLOGY, vol. 10, 1 January 2019 (2019-01-01), pages 1047, XP055797688, DOI: 10.3389/fimmu.2019.01047
Attorney, Agent or Firm:
DOHERTY, Elizabeth A. et al. (US)
Download PDF: